Quick Facts
FONT-SIZE Plus   Neg
Share SHARE
mail  E-MAIL

Ventrus Biosciences Unveils Positive Results Of Its Phase 3 Trial Of Diltiazem

5/14/2012 7:28 AM ET

Development stage pharmaceutical company Ventrus Biosciences Inc (VTUS: Quote) Monday released positive results from its Phase 3, randomized, double-blind, placebo-controlled clinical trial of diltiazem hydrochloride cream in patients with anal fissures.

Ventrus further added that its development partner S.L.A Pharma has completed most of the outputs for the statistical analysis plan of the Phase 3 trial,

Ventrus revealed that the Phase 3 study randomized 465 subjects to diltiazem hydrochloride 4% or 2% w/w cream, or placebo, applied topically three times daily for 8 weeks, followed by a 4 week blinded observation period.

The pharmaceutical company revealed that both 4% and 2% diltiazem treatment arms demonstrated significant improvements compared to placebo in the primary endpoint of average of worst anal pain associated with or following defecation and in the secondary endpoints of overall anal-fissure-related pain and anal fissure healing Pain endpoints were assessed using an 11-point numerical pain rating scale.

"These results mark a watershed event for Ventrus, in that they highlight the potential for VEN 307 to be a treatment of choice for anal fissures and set off a potentially transformative period for the Company," said Russell H. Ellison, M.D., M.Sc., Chairman and Chief Executive Officer of Ventrus Biosciences, Inc.

Register
To receive FREE breaking news email alerts for Ventrus Biosciences Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Existing home sales in the U.S. saw a modest increase in the month of April, according to a report released by the National Association of Realtors on Wednesday. NAR said existing home sales climbed 0.6 percent to a seasonally adjusted annual rate of 4.97 million in April from an upwardly revised 4.94 million in March. Federal Reserve Chairman Ben Bernanke on Wednesday downplayed speculation that the central bank is planning to taper its $85 billion monthly bond buying program. The economic recovery remains too fragile to proceed without extraordinary support from the Fed in light of fiscal restraint and headwinds... Stocks have moved modestly higher in early trading on Wednesday, adding to the slim gains posted in the previous session. The major averages have all climbed into positive territory, although buying interest has remained relatively subdued. The major averages have seen some further upside in recent trading, reaching new highs for the young session.
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.